Recent moves in the industry include C-suite shuffles at AbbVie, Abivax and Ikena Oncology, plus I-Mab.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.
A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.
The company hopes the drug will become the standard of care rescue treatment in asthma.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.
The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.
Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.
